United Therapeutics is touting data from a late-stage study of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension. The primary efficacy endpoint of the trial was the change in six-minute walk distance at 12 weeks measured at peak exposure, defined by the trial protocol as 10-60 minutes after inhalation of Viveta, relative to baseline. "Preliminary analysis of the TRIUMPH-1 results demonstrates an improvement in median 6MW distance by approximately 20 meters in patients receiving Viveta as compared to patients receiving placebo."
- read the release for more info